Equities researchers at Wedbush initiated coverage on shares of Clementia Pharm (NASDAQ:CMTA) in a report issued on Monday. The brokerage set an “outperform” rating and a $26.00 price target on the stock. Wedbush’s target price suggests a potential upside of 61.49% from the stock’s previous close.

Separately, Morgan Stanley assumed coverage on Clementia Pharm in a research report on Monday. They issued an “overweight” rating and a $27.00 price target for the company.

Shares of Clementia Pharm (NASDAQ:CMTA) opened at 16.10 on Monday. Clementia Pharm has a 52 week low of $15.05 and a 52 week high of $18.95. The stock’s market cap is $491.48 million. The firm has a 50-day moving average price of $14.97 and a 200 day moving average price of $14.97.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another domain, it was copied illegally and republished in violation of United States and international trademark and copyright legislation. The legal version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/08/30/clementia-pharm-cmta-now-covered-by-wedbush.html.

Clementia Pharm Company Profile

Clementia Pharmaceuticals Inc is a clinical stage biopharmaceutical company. The Company is engaged in developing disease-modifying treatments for patients suffering from debilitating bone and other diseases with high unmet medical need. Its lead product candidate, palovarotene, is an oral small molecule that binds and activates retinoic acid receptor gamma (an RARg agonist), and has activity in preventing abnormal new bone formation as well as scar tissue formation (or fibrosis) in a variety of tissues in animal models.

Receive News & Stock Ratings for Clementia Pharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clementia Pharm and related stocks with our FREE daily email newsletter.